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Abstract
Purpose Genome-wide association studies (GWAS) have led to the identification of a bladder cancer susceptibility variant
(rs710521) in a non-coding intergenic region between the TP63 and LEPREL1 genes on chromosome 3q28, suggesting a role in
the transcriptional regulation of these genes. In this study, we aimed to functionally characterize the 3q28 bladder cancer risk locus.
Methods Fine-mapping was performed by focusing on the region surrounding rs710521, and variants were prioritized for further
experiments using ENCODE regulatory data. The enhancer activity of the identified region was evaluated using dual-luciferase
assays. CRISPR/Cas9-mediated deletion of the enhancer region was performed and the effect of this deletion on cell proliferation
and gene expression levels was evaluated using CellTiter-Glo and RT-qPCR, respectively.
Results Fine-mapping of the GWAS signal region led to the identification of twenty SNPs that showed a stronger association
with bladder cancer risk than rs710521. Using publicly available data on regulatory elements and sequences, an enhancer region
containing the bladder cancer risk variants was identified. Through reporter assays, we found that the presence of the enhancer
region significantly increased ΔNTP63 promoter activity in bladder cancer-derived cell lines. CRISPR/Cas9-mediated deletion
of the enhancer region reduced the viability of bladder cancer cells by decreasing the expression of ΔNTP63 and p63 target
genes.
Conclusions Taken together, our data show that bladder cancer risk-associated variants on chromosome 3q28 are located in an
active enhancer region. Further characterization of the allele-specific activity of the identified enhancer and its target genes may
lead to the identification of novel signaling pathways involved in bladder carcinogenesis.
Keywords Bladder cancer . TP63 gene . LEPREL1 gene . Enhancer . Genome-wide association study . Single-nucleotide
polymorphism
1 Introduction
In recent years, bladder cancer risk loci have been identified
through genome-wide association studies (GWAS) [1]. Until
now, 14 bladder cancer risk loci, including TP63, c-MYC [2],
TERT/CLPTM1L [3], FGFR3/TACC3 [4], PSCA [5],
APOBEC3A/CBX6, CCNE1, UGT1A [6], SLC14A1 [7, 8],
JAG1 [9, 10], TERC, LSP1 [10] and MCF2L [11] have been
described. The GWAS-identified variants are unlikely func-
tional by themselves. Instead, identified single-nucleotide
polymorphisms (SNPs) are often correlated to the actual
(unmeasured) causal variants, and hence further fine-
mapping is required. Moreover, they mostly map to non-
coding intronic and intergenic regions [12]. Finding the caus-
ative SNPs proved to be challenging and only four of the
GWAS-identified bladder risk loci, including PSCA,
UGT1A, CCNE1 and APOBEC3B, have been functionally
characterized, showing allele-specific regulation of gene ex-
pression [5, 13–16].
The importance of non-coding regions in the regulation of
gene expression has been demonstrated by the Encyclopedia
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of DNA Elements (ENCODE) initiative. ENCODE data re-
vealed that GWAS-identified risk SNPs are significantly
enriched in active regulatory regions, which are often cell type
and disease specific [17, 18]. The presence of a SNP in a non-
coding region can alter gene expression levels both in cis
(locally) and in trans (distally) via multiple mechanisms
[19]. For example, one of the most studied colorectal cancer
risk SNPs (rs6983267), located in a 8q24 gene desert [20],
was found to enhance binding of the TCF4 transcription factor
in an enhancer region [21]. This enhancer interacts with the c-
MYC promoter and modulates its activity in an allele-specific
manner [22, 23], leading to increased c-MYC expression in the
presence of the risk allele [24]. Later it was found that
rs6983267 lies within a long non-coding RNA, CCAT2, and
that colorectal cancer cell lines express significantly higher
levels of CCAT2 transcripts containing the risk G allele.
CCAT2 was found to positively regulate c-MYC transcription
levels and thereby to affect the growth, metastasis and energy
metabolism of colorectal cancer cells in an allele-specific
manner [25].
One of the bladder cancer risk SNPs, rs710521 (A > G
variant, A is risk-increasing allele) is located in an intergenic
region between TP63 and LEPREL1 on chromosome 3q28, in
a linkage disequilibrium (LD) block encompassing the TP63
gene [2], which codes for a member of the p53 family of
transcription factors. TP63 encodes two isoforms: TATP63
and ΔNTP63, which have opposite effects on cell cycle reg-
ulation and apoptosis. Furthermore, it has been found that p63
expression plays a role in epithelial development and the for-
mation of squamous epithelium. It has also been found to play
a role in cancer development [26]. In non-muscle invasive
bladder cancer (NMIBC), altered p63 expression has been
found to be inversely correlated with pathological grade,
whereas in muscle invasive tumors (MIBC) p63 expression
has been found to be frequently down-regulated [27]. The
second gene within the 3q28 locus, LEPREL1, encodes a
member of the Leprecan family of proteoglycans, involved
in posttranslational modification of collagen, leading to pro-
tein stability [28]. The expression of LEPREL1 has been
found to be down-regulated in breast cancer [29] and hepato-
cellular carcinoma [30] and to be up-regulated in thyroid can-
cer [31].
In our study, we aimed at fine-mapping the original
GWAS signal, rs710521, within the TP63/LEPREL1 gene
locus and, subsequently, at a functional characterization of
genetic variants within this locus that are associated with
bladder cancer risk. Using publicly available regulatory
data an enhancer region containing the fine-mapped blad-
der cancer risk SNPs was identified. We found that the
presence of the identified enhancer increased ΔNTP63
promoter activity and affected cell viability. From our data
we conclude that the bladder cancer-associated SNPs at the
3q28 locus map to an enhancer element that contributes to
bladder cancer development by modulating gene expres-
sion levels.
2 Materials and methods
2.1 Regional association analysis
Fine-mapping was based on association analysis of imputed
single nucleotide variant (SNV) data in the 500 kb region
surrounding rs710521 in 1601 bladder cancer patients and
1819 controls from the Nijmegen Bladder Cancer Study
(NBCS) [8]. The NBCS participants were genotyped using
either the Illumina Human370CNV-Duo or the Quad
BeadChip and imputed using IMPUTE v2.1 software [32] in
conjunction with a training set consisting of the combined
1000 Genomes low-coverage pilot haplotypes (released June
2010, 120 chromosomes) and the HapMap3 haplotypes (re-
leased February 2009, 1920 chromosomes). Individuals with
< 96% yield for the 292,650 autosomal SNPs present on both
chips and SNPs with a minor allele frequency < 0.01, which
were not in Hardy-Weinberg equilibrium (P < 10–5), or with a
different frequency for the two chip types used (P < 10–5),
were excluded from the imputation. Statistical case-control
association analyses for all SNVs were performed using
SNPtest (version 2.4) [33] with the most common homozy-
gous genotype as reference genotype.
2.2 Prioritization of variants
The variants that showed a stronger association (in terms of p-
value) with bladder cancer risk than rs710521 were prioritized
for further analysis using the ENCODE data [17, 34],
Regulome DB [35] and the Haploreg database [19]. The pres-
ence of histone modifications associated with active chroma-
tin, DNaseI hypersensitive sites and binding of transcription
factors was used to select potential active regulatory regions
[36].
2.3 Cell culture
The bladder cancer-derived cell lines 5637 (ATCC: HTB-9,
Manassas, Virginia, USA), 647 V (DSMZ: ACC-414,
Braunschweig, Germany), RT-112 (DSMZ: ACC-418),
SW800 [37] and T24 (ATCC: HTB-4) were grown in
RPMI-1640 medium (Invitrogen, Carlsbad, California,
USA) supplemented with 10% fetal calf serum (Sigma-
Aldrich, St.Louis, Missouri, USA) and L-glutamine. The cells
were cultured in a humidified atmosphere at 37 °C and 5%
CO2. All cell lines were authenticated in 2016 using the
PowerPlex 21 PCR kit (Promega, Madison, Wisconsin,
USA) by Eurofins Genomics (Ebersberg, Germany) and test-
ed mycoplasma-free.
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2.4 Formaldehyde-assisted isolation of regulatory
elements (FAIRE)
FAIRE analysis was performed as described previously [38].
Briefly, 647 Vand RT112 bladder cancer cells were seeded in
10-cm culture dishes. When confluent, cells were cross-linked
using 37% formaldehyde (Sigma-Aldrich) for 5 min.
Subsequently, cross-linked cells were lysed and cell lysates
were sonicated on ice using a Bioruptor sonicator
(Diagenode, Seraing, Belgium) for 15 min (15 cycles of
30 s. on, 30 s. off). The input control DNA and FAIRE
DNAwere isolated according to the manufacturer’s protocol.
FAIRE enrichment was measured by FAIRE-qPCR using 5 μl
(~5 ng/μl) DNA as input, SYBRGreen qPCR reagent (Roche)
and a LightCycler LC480 instrument (Roche). The relative
FAIRE enrichment for each amplicon was calculated as the
ratio for the signal from the FAIRE sample relative to the
signal from the input control DNA. The primers used are listed
in Supplementary Table 1.
2.5 Cloning of enhancer reporter vectors
DNA was isolated from fresh frozen tissue samples (normal
bladder adjacent to tumor) using a QIAamp DNA Mini kit
(QIAGEN, Hilden, Germany), according to manufacturer’s
instructions. The ΔNTP63 promoter region [39], the
LEPREL1 promoter region and the intergenic enhancer region
were PCR-amplified using PrimeSTAR HS DNA polymerase
and a GC buffer (Takara, Shiga, Japan). The primer sequences
used are listed in Supplementary Table 1. For isolation of the
enhancer (E1) containing the risk and the non-risk haplotypes
(AA and GG, respectively), the region encompassing
rs4687103 and rs4687104 was amplified. Haplotypes were
determined using Haploview software [40]. The ΔNTP63
promoter region and the LEPREL1 promoter region were li-
gated into a pGL3-Basic vector (Promega), upstream of the
luciferase gene, using BglII andHindIII restriction sites (NEB,
Ipswich, Massachusetts, USA). Next, the enhancer region was
cloned into the pGL3-ΔNTP63 promoter and the pGL3-
LEPREL1 promoter containing vectors, downstream of the
luciferase gene using BamHI and SalI restriction sites (New
England Biolabs, NEB). Plasmid DNA was isolated using a
QIAGEN Plasmid Midi kit (QIAGEN). All reactions were
performed according to the manufacturer’s instructions. The
integrity of the vectors was confirmed by Sanger sequencing
(Sequencing Facility, Department of Genetics, Radboud uni-
versity medical center, Nijmegen, The Netherlands).
2.6 Enhancer reporter assays
Bladder cancer-derived cells were seeded in 96-well plates. At
70–80% confluency, the cells were transfected with 900 ng
reporter vector and 100 ng pRL-TK control vector (Promega)
using X-tremeGENE 9 transfection reagent (Roche), accord-
ing to manufacturer’s instructions. Two days after transfec-
tion, enhancer reporter assays were performed using a Dual-
Luciferase reporter assay system (Promega) according to the
manufacturer’s instructions. Luciferase activity was measured
using a Victor3 multilabel reader (PerkinElmer, Waltham,
Massachusetts, USA). The Firefly luciferase signals were nor-
malized to the Renilla luciferase signals. All experiments were
performed in triplicate and repeated at least three times. Data
were compared to the pGL3-ΔNTP63 or pGL3-LEPREL1
promoter activities in each experiment.
2.7 Cloning of CRISPR/Cas9 genome editing vectors
Guide RNAs (gRNAs) targeting the TP63 enhancer region
were designed using the CRISPR Design tool (http://crispr.
mit.edu). The gRNAs sequences are listed in Supplementary
Table 1. The gRNA cloning vector was a gift from George
Church (Addgene plasmid #41824) [41]. The gRNAs and
gRNA vector were modified as described before [42]. The
oligonucleotides were synthesized (Invitrogen) and annealed
according to the gRNA design and cloning protocol from the
Church Laboratory (Addgene) using Phusion DNA polymer-
ase (NEB). The gRNA cloning vector was linearized using
AflII (NEB) and inserts containing target sequences were in-
corporated into the gRNA vector using Gibson assembly
(NEB), according to manufacturer’s instructions. Cloning
products were transformed into DH5α competent E.coli
(NEB) cells. Plasmid DNA isolation and DNA sequence anal-
yses were performed as described above.
2.8 CRISPR/Cas9-mediated deletion of the TP63 E1
enhancer region
5637 bladder cancer-derived cells were seeded in 6-well
plates. At 70–80% confluency the cells were co-transfected
with a hCas9 expression vector (a gift from George Church,
Addgene plasmid #41815) [41] and two gRNA vectors
(targeting the regions flanking the enhancer), using X-
tremeGENE 9 transfection reagent (Roche) according to the
manufacturer’s instructions. Three days after transfection, the
cells were trypsinized and seeded at low densities in 10-cm
dishes. The remaining cells were used for DNA isolation
using a QIAamp DNA Mini Kit (QIAGEN) after which
deletion-specific PCR was performed using SuperTaq DNA
polymerase (ThermoFisher Scient i f ic , Wal tham,
Massachusetts, USA). Deletion of the 2.2 kb E1 enhancer
region was confirmed by agarose gel electrophoresis and
Sanger sequencing of the PCR amplicons. The ratio between
non-deleted and deleted cells was used to evaluate the effi-
ciency of the CRISPR/Cas9 system (Supplementary Fig. A).
After 2 weeks, single cell colonies were harvested and DNA
was isolated using a NucleoSpin Tissue XS kit (Macherey-
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Nagel, Düren, Germany). Deletion-specific PCR was per-
formed (as above) to identify and select E1-deleted clones
(see Supplementary Fig. B).
2.9 RNA isolation and RT-qPCR
CRISPR/Cas9 deleted cell lines were seeded in 6-well plates.
At 70–80% confluency, total RNAwas isolated using TRIzol
reagent (Invitrogen). The RNA yield was evaluated using a
Nanodrop ND-1000 system (ThermoFisher Scientific). RNA
was DNaseI treated, and cDNAwas synthesized using random
hexamer primers in conjunction with Superscript II reverse
transcriptase (Invitrogen). Gene expression was evaluated by
SYBRGreen qPCR analysis (Roche) on a LightCycler LC480
instrument (Roche). Human Heterochromatin Protein 1,
Binding Protein 3 (HP1BP3) mRNA expression was used
for normalization. Relative gene expression was calculated
using theΔΔCt method, and all data were compared to those
of wild-type, non-deleted cells. The primer sequences used are
listed in Supplementary Table 1.
2.10 Cell viability assay
Cells were seeded into 96-well plates, after which cell viability
was assessed at different time points using a CellTiter-Glo
luminescence assay (Promega) according to the manufac-
turer’s instructions. Luminescence was measured using a
Victor3 multilabel reader (PerkinElmer). Each experiment
was performed in triplicate and repeated at least three times.
All data were compared to those of non-deleted cells.
2.11 Correlation of gene expression levels
with rs4687103 genotypes
To perform expression quantitative loci (eQTL) analysis,
rs4687103 genotype data from 412 MIBC patients were
downloaded from The Cancer Genome Atlas (TCGA) project
[43]. Only patients from Utah residents of northern and west-
ern European ancestry (CEU) were included (n = 297). Gene
expression data were downloaded from the Broad Institute
GDAC Firehose (gdac.broadinstitute.org). From 297 MIBC
patients, cases with alterations in the TP63 and/or LEPREL1
loci or p63 target genes as shown in cBioPortal [44, 45] were
excluded from eQTL analysis (n = 27, 35, 23, 31, 15 and 15
for TP63, LEPREL1, FGFR3, NOTCH1, KRT5 and KRT6A,
respectively). Gene expression levels were compared between
genotypes (GG and GA and AA). Clinical data were
downloaded from cBioPortal [44, 45].
2.12 Statistical analysis
Statistical analyses of data from the FAIRE assays, the en-
hancer reporter assays, and the cell proliferation and gene
expression assays were performed using GraphPad and a
one-way ANOVA test. Associations between survival and
rs4687103 genotype were analyzed using IBM SPSS and
Kaplan-Meier analysis (log-rank test). For all analyses a p-
value < 0.05 was considered significant.
3 Results
3.1 Association analysis of the rs710521 region
In the analyzed set of bladder cancer patients and controls, the
odds ratio (OR) for rs710521 GA versus AAwas 0.78 (95%
confidence interval 0.68–0.90) and for GG versus AA 0.69
(95% CI 0.52–0.91) with a p-value for association (general
genotype model) of 0.00034741. There were 20 SNPs that
showed a stronger association with reduced bladder cancer
risk. These were all in strong linkage disequilibrium (LD;
r2 > 0.8) with rs710521 and showed similar allele frequencies
and ORs (Fig. 1a, Supplementary Table 2).
3.2 In silico analysis of potential regulatory activity
of the bladder cancer risk SNPs
Although the interpretation of non-coding GWAS-identified
variants is challenging, several characteristics of the DNA
regions containing functional variants have been described
[19, 36]. In order to prioritize the 21 bladder cancer-
associated SNPs within the TP63 region, we used publicly
Fig. 1 Fine-mapping of the original GWAS hit, rs710521, on 3q28. a
Regional association plot showing SNPs in 3q28 and their association
with bladder cancer risk. In total 20 SNPs are associated with bladder
cancer risk (i.e. their p-values (y-axis) are equal/lower than those for
rs710521 (purple dot) and are in high LD with rs710521 (r2 > 0.8). The
SNPs are colored based on LD (r2) and their genomic positions are based
on the hg19 EUR November 2014 version of the reference genome. The
plot was created using LocusZoom software [46]. bDetailed overview of
the TP63 and LEPREL1 gene locus, containing the 20 fine-mapped blad-
der cancer risk SNPs. The identified SNPs cluster in and around two
enhancer regions (E1 and E2), which were assigned as enhancers based
on the ENCODE regulatory data (i.e., presence of H3K27Ac histone
marks, DNaseI hypersensitive sites and transcription factor binding sites).
Rs4687100 maps to the last intron of the TP63 gene. Rs1839072,
rs35868376, rs1447932, rs1447933, rs4479569, rs4687103, rs4687104,
rs34666239, rs35076301 and rs35075630 map to enhancer region 1 (E1).
Rs13089435 is located close to E1 in a region were H2K27Ac marks are
absent (not shown). Rs62278269, rs35392448, rs13059523, rs12491886,
rs12485497 and rs4687108 are located in a non-active region (NA).
Rs837775 is located upstream of E2 in the non-active region. The original
GWAS SNP, rs710521 (marked in red) and rs56031831 are located in E2.
The numbers in the DNase clusters represent the number of ENCODE
cell lines in which the region was DNase sensitive. The regulatory data
for urothelia show the DNaseI hypersensitive peak and enrichment in the
open chromatin structure revealed by FAIRE. Txn: transcription factor
binding based on ChIP analysis. The images were downloaded from the
UCSC Genome Browser (hg19) [47] and modified
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available regulatory data [19, 34, 35] (Supplementary
Table 3). Depending on the database used, 57.2 to 85.7% of
the SNPs were found to be located in regions containing his-
tone marks characteristic for enhancers, 19.1 to 33.3% of the
SNPs were found to be located in DNaseI hypersensitive sites,
and 17 SNPs were predicted to alter transcription factor bind-
ing sites. Two SNPs, rs4687103 and rs4687104, were found to
be located in multiple transcription factor binding sites (Fig.
1b). Rs4687104 is the only variant that was predicted to alter
transcription factor binding motifs (Regulome DB,
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Supplementary Table 3). Moreover, rs4687104 was found to
lie within an active chromatin region in urothelium (marked
by a DNaseI hypersensitive, nucleosome-free site) [35], sug-
gesting its potential for regulatory activity. Based on the pres-
ence of active histone modifications, DNaseI hypersensitivity,
open chromatin structure and the presence of transcription
factor binding sites, we selected a putative enhancer region 1
(E1), containing rs1839072, rs35868376, rs1447932,
rs1447933, rs4479569, rs4687103, rs4687104, rs34666239,
rs35076301 and rs35075630, for further functional studies
(Fig. 1b).
3.3 The enhancer 1 region lies
within nucleosome-depleted, active chromatin
To confirm that the identified putative enhancer region lies
within an active, open chromatin region as shown by the
ENCODE data (Fig. 1b), we analyzed its nucleosome occu-
pancy in bladder cancer cells using FAIRE analysis. In two
bladder cancer-derived cell lines, RT112 and 647 V, the iden-
tified enhancer region E1 showed a significant FAIRE enrich-
ment, confirming nucleosome-depletion and thus an open
chromatin structure. The region surrounding rs4687103 in
the E1 region showed a higher FAIRE enrichment compared
to a non-active heterochromatin region within the TP63/
LEPREL1 locus, and compared to the non-expressed pros-
tate-specific PCA3 gene locus. Additionally, the enrichment
in active chromatin in the identified enhancer region was
found to be similar to the c-MYC promoter region, supporting
its potential regulatory activity in bladder cancer cells
(Fig. 2a).
3.4 The E1 enhancer region affects ΔNTP63
and LEPREL1 promoter activity
Because of the role of enhancer regions in the regulation of
gene expression, we hypothesized that the identified enhancer
region containing the bladder cancer risk SNPs may (allele-
specifically) activate the ΔNTP63 (the TP63 isoform that is
most abundantly expressed in normal urothelium and bladder
cancer, data not shown) and/or LEPREL1 gene promoter ac-
tivities in cis. We created reporter vectors containing the
ΔNTP63 or LEPREL1 promoter and the identified E1 enhanc-
er region, the latter containing both the risk and the non-risk
haplotypes (Fig. 2b). We found that the presence of the E1
fragment, harboring most of the transcription factor binding
sites (containing rs4687103 and rs4687104), significantly in-
creasedΔNTP63 promoter activity in the presence of both the
minor and the major alleles in all three cell line models tested
(Fig. 2c). In contrast to the ΔNTP63 promoter, no regulatory
effect of E1 on LEPREL1 promoter activity was observed
(Fig. 2d). Also, no significant allele-specific effects on E1
enhancer activity were observed (Fig. 2c and d).
3.5 Deletion of the E1 enhancer region affects cell
viability and TP63 expression
We further evaluated the cellular effects of the identified en-
hancer region by deleting it in 5637 cells using CRISPR/Cas9
technology (Fig. 3a, Supplementary Fig. 1A-B). We found
that homozygous deletion of enhancer region E1 significantly
decreased cell viability compared to wild-type, non-deleted
cells (Fig. 3b). Heterozygous deletion of E1 using gRNA set
1 also led to decreased cell viability compared to non-deleted
cells, although to a lesser extent than in homozygous E1 de-
leted cells (Fig. 3b). Homozygous and heterozygous deletion
of E1 affected gene expression in cis by decreasing ΔNTP63
levels (Fig. 3c). Interestingly, expression of the TP63-flanking
gene LEPREL1 was found to be decreased in E1-deleted cells
as well (Fig. 3d). Additionally, the expression levels of two
reported p63 target genes, FGFR3 [48] and NOTCH1 [49],
were evaluated. ΔNTP63 expression was found to be posi-
tively correlated with FGFR3 and NOTCH1 expression in
no rma l u r o t h e l i um and MIBC t i s s u e s amp l e s
(Supplementary Fig. 2). Interestingly, the FGFR3 and
NOTCH1 expression levels were also found to be decreased
in E1-deleted cells (Fig. 3e and f, respectively).
3.6 Correlation of gene expression with rs4687103
genotype
The presence of a SNP may affect gene expression in
an allele-specific manner, resulting in differences in
gene expression levels between individuals [50].
Concordantly, TP63 expression was found to be up-
regulated in individuals homozygous for the G allele
in comparison to heterozygous individuals (Fig. 4a).
No significant differences between LEPREL1 expression
levels and rs4687103 genotypes were found (Fig. 4b).
The expression levels of one of the p63 target genes,
NOTCH1, was found to correlate with the rs4687103
genotype. Individuals homozygous for the non-risk G
allele exhibited significantly higher NOTCH1 expression
levels compared to carriers of the risk A allele (Fig. 4c).
No allele-specific expression of FGFR3, another p63
target gene, was found (Fig. 4d). Moreover, the expres-
sion levels of KRT5 (Fig. 4e), but not KRT6A (Fig. 4f),
were also found to be significantly higher in individuals
homozygous for the non-risk G allele. We further eval-
uated the effect of the rs4687103 genotype on survival
using a set of 297 muscle-invasive tumors from the
TCGA project [43]. No significant differences in overall
survival (OS) were observed (p = 0.178, Supplementary
Fig. 3A), although a trend towards a shorter OS in
MIBC for GG versus GA/AA genotypes was found
(p = 0.065, Supplementary Fig. 3B).
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4 Discussion
Susceptibility to bladder cancer has been shown to be modi-
fied by complex interactions between genetic and environ-
mental factors [51]. Several genetic variants have been iden-
tified that are associated with bladder cancer risk, which point
to novel genes and mechanisms involved in bladder cancer
development [12]. Here, we fine-mapped a GWAS signal at
the 3q28 locus and showed that a region containing the blad-
der cancer-associated SNPs regulate gene expression levels
and modulate cell survival.
Using publicly available data for regulatory elements, we
identified an enhancer region that significantly increased
ΔNTP63 promoter activity in bladder cancer-derived cells,
although not in an allele-specific manner. Genetic variants
identified by GWAS are usually associated with small risks
and their effects on gene expression levels may be modest
[12]. Therefore, the sensitivity of the current assays may not
be sufficient to reveal allele-specific effects. Furthermore, an
enhancer region may regulate multiple target genes and a sin-
gle gene may be regulated by multiple enhancer elements.
CRISPR/Cas9 genome editing allows for assessment of the
impact of a single genetic variant within particular genomic
and/or cell type contexts [52]. Improvements in the efficiency
of CRISPR/Cas9-mediated homology directed repair (HDR)
[53] may facilitate functional studies of GWAS-identified var-
iants in the future. The expression of transcription factors is
tightly controlled and hence no significant, allele-specific ef-
fect on the promoter activity and expression of transcription
factors (TFs) may be observed. However, allele-specific dif-
ferences could be manifested through expression of TF-target
genes [54]. We indeed found that the expression levels of the
ΔNTP63 target gene NOTCH1 significantly correlated with
the risk SNP genotype. The Notch signaling pathway has been
shown to be involved in bladder cancer development, al-
though it is not clear yet whether Notch signaling is oncogenic
or tumor suppressive. For example, high expression of
Jagged2 (a NOTCH ligand) has been shown to be associ-
ated with tumor aggressiveness and the formation of me-
tastases [55]. Other studies have shown that NOTCH
inactivating mutations in vivo accelerated the development
of bladder cancer and promoted the formation of squamous
cell carcinoma [56, 57].
In MIBC tissue specimens, the levels of ΔNTP63 do cor-
relate with the risk SNP genotype. Previously, it was found
that in response to genotoxic stress ΔN-p63 is recruited to a
Fig. 2 ΔNTP63/LEPREL1 promoter activity analysis of the E1 enhancer.
a Enrichment in the open, nucleosome-depleted chromatin in the E1
enhancer region in two bladder cancer-derived cell lines, RT112 and
647 V, analyzed by FAIRE. All data are normalized to a non-active region
within the TP63/LEPREL1 locus. b Schematic overview of the reporter
vector (pGL3-ΔNTP63 promoter-enhancer) used for promoter-enhancer
assays. Enhancer activity in 5637 (TP63 positive) and T24 and SW800
(TP63 negative) cells, using the enhancer part containing rs4687104 and
rs4687103 with either the minor (non-risk) or the major (risk) alleles, on c
ΔNTP63 and d LEPREL1 promoter activity is shown. Data are compared
to the pGL3- ΔNTP63 promoter or the pGL3-LEPREL1 promoter-only
construct, respectively (dashed line). All experiments were performed in
triplicate and repeated at least three times using independent plasmid
DNA isolations. Bars represent mean ± SD; *p < 0.05; ** p < 0.01;
*** p < 0,001
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p53-binding element in its own promoter leading to silencing
of ΔNTP63 expression [58]. Smoking is the most important
risk factor for developing bladder cancer, accounting for 50%
of the tumors [51]. Therefore, it is plausible that the modest
allele-specific differences in ΔNTP63 expression are mani-
fested upon (smoking-induced) DNA damage. Moreover,
eQTL discovery in tumor tissue has been shown to be chal-
lenging due to frequent genetic and epigenetic alterations af-
fecting transcript levels [54].
In our study, the deletion of the enhancer region in the
5637 bladder cancer-derived cell line led to decreases in
ΔNTP63 and p63 target gene mRNA expression levels,
subsequently affecting cell viability. Similarly, it has pre-
viously been shown that shRNA-mediated silencing of
ΔNTP63 expression in 5637 bladder cancer cells resulted
in cell cycle arrest, a decreased proliferation rate and
Cyclin D1 downregulation. Moreover, it has been reported
that also in a 5637 xenograft model in mice, knockdown of
Fig. 3 Functional effects of CRISPR/Cas9-mediated deletion of the E1
enhancer region in 5637 bladder cancer-derived cells. a Experimental
approach used for deletion of enhancer E1 in 5637 cells using a set of
gRNAs flanking the identified enhancer region and the wild-type Cas9
protein. The enhancer region was targeted using 2 independent sets of
gRNAs (gRNA 1 and gRNA 2). The effects of the deletion on b cell
viability and c ΔNTP63 and d LEPREL1 gene expression levels are
shown, as well as the effect of the deletion on the expression levels of
the p63 target genes FGFR3 (e) and NOTCH1 (f). All data from E1-
deleted cells from single cell colonies are compared to the average values
in wild-type, non-deleted, cells from corresponding experiments. All ex-
periments were performed in triplicate and repeated at least three times.
Bars represent mean ± SD; homo, homozygous deletion; hetero, hetero-
zygous deletion; * p < 0.05; ** p < 0.01; *** p < 0.001
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ΔNTP63 inhibited tumor growth through induction of ap-
optosis [59]. In another study, knockdown of ΔNTP63 was
found to increase adhesion and to decrease migration of
5637 cells by increasing F-actin levels [60]. Interestingly,
reduced ΔNTP63 expression has been found to sensitize
5637 bladder cancer cells to DNA damage-induced apo-
ptosis independent of p53 [61]. In contrast, Fukushima et
al. showed thatΔNTP63 knockdown led to upregulation of
N-cadherin and increased motility and invasion of 5637
cells [62].
We found that deletion of the identified enhancer re-
gion E1 led to a decrease in both ΔNTP63 and LEPREL1
expression levels. In thyroid carcinoma, LEPREL1 has
been found to serve as a target of the TWIST1 transcrip-
tion factor (associated with epithelial-to-mesenchymal
transition, metastasis formation and a poor prognosis). In
addition, it has been reported that down-regulation of
LEPREL1 significantly reduced the growth of thyroid
cancer cells [31]. In hepatocellular and breast cancer over-
expression of LEPREL1 has been found to inhibit cell
proliferation and colony formation [29, 30]. Until now,
however, the role of LEPREL1 has not been studied in
bladder cancer.
Luminal and basal subtypes of MIBC have been identi-
fied by several groups [43, 63–66]. The basal subtype has
been shown to be associated with a shorter overall survival
and to be characterized by deregulation of p63 target genes
[65]. High expression of basal keratins, such as KRT5 and
KRT6A, is the most characteristic feature of the basal sub-
type of bladder cancer [63]. ΔNp63 has been shown to
regulate KRT5 and KRT6A gene expression in several tis-
sues [65, 67, 68]. The rs4687103 non-risk allele was found
to be significantly correlated with increased KRT5, but not
KRT6A, expression, suggesting that the risk locus on 3q28
stimulates basal/squamous differentiation of the tumors,
with a shorter overall survival.
Multiple transcription factor binding sites have been
shown to overlap the rs4687103 and rs4687104 SNPs in
the TP63 E1 enhancer region, including proteins known
to be involved in basal/squamous bladder cancer subtype
development, like STAT3 and c-MYC [65, 66]. Moreover,
STAT3, FOS, c-MYC and CEBPB transcription factors
Fig. 4 Correlations between
rs4687103 genotype and a TP63,
b LEPREL1, c NOTCH1, d
FGFR3, e KRT5 and f KRT6A
expression levels in MIBC. The
whiskers represent 10th and 90th
percentile. The line represents
median. + mean; * p < 0.05; **
p < 0.01
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have been found to bind to the promoter regions of the
KRT5 and KRT6A genes [66]. Further studies are required
to evaluate which transcription factors can bind to the E1
enhancer in an allele-specific manner, both in normal
urothelium and in bladder cancer cells.
Genome-wide association studies have successfully led
to the identification of genetic variants that modulate gene
expression levels in bladder cancer. The presence of
rs2294008, a missense variant in the PSCA gene, has been
found to lead to formation of a truncated PSCA protein, due
to alteration of the start codon. The presence of the variant
allele has been found to be associated with reduced PSCA
promoter activity [5]. The protective T allele of rs17863783
within the UGT1A locus has been found to be associated
with increased UGT1A6.1 expression, leading to a higher
clearance of carcinogens from the urothelium and a de-
creased bladder cancer risk [15]. In addition, urine concen-
tration was found to be significantly decreased in carriers of
the risk T allele of rs10775480 (intron of SLC14A1) [69]. In
the CCNE1 locus, the original GWAS-identified SNP
rs8102137 and a CCNE1 promoter variant rs7257330 were
found to be associated with bladder cancer aggressiveness,
marked by increased CCNE1 protein expression [14].
APOBEC3B expression and enrichment in APOBEC3B-
signature mutations have been shown to correlate with
rs1014971. Moreover, the presence of a SNP within the
non-coding region upstream of APOBEC3A has been found
to affect binding of proteins in an allele-specific manner
[16]. Recently, Wang et al. identified a bladder cancer risk
variant within the 3’-UTR of the TP63 gene. The presence
of this variant was shown to disrupt miR-140-5p binding
leading to al le le-specif ic TP63 expression [70] .
Additional functional studies are warranted to uncover the
molecular mechanisms by which this and other GWAS-
identified SNPs influence bladder cancer risk.
In conclusion, we identified an enhancer region within the
TP63/LEPREL1 intergenic locus containing bladder cancer
risk SNPs that regulate gene expression levels in cis and,
subsequently, tumor cell viability. Our study underlines the
importance of GWAS-identified signals in non-coding regions
for bladder cancer development. Further characterization of
the identified region may unravel novel allele-specific path-
ways involved in the modulation of bladder cancer
susceptibility.
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